Clinical trials: Pneumococcal Infectious Diseases
- Condition Pneumococcal Infectious Diseases
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pneumococcal Infectious Diseases
A Lot-to-Lot Consistency Clinical Trial of PCV13
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.
- Trial name
- NCT07832500
- Testing
- Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3
- Where
- China
- Volunteers
- 1,125 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Children Aged 2-17 Years
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years.
- Trial name
- NCT06550830
- Testing
- Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13®
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving…
- Trial name
- NCT06720038
- Testing
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Infectious Diseases
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
- Trial name
- NCT07593924
- Testing
- Sinovac PCV13, Prevenar 13™
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infectious Disease
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years…
- Trial name
- NCT07071701
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- China
- Volunteers
- 19,267 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Otitis Media, Otitis Media With Effusion
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
The aim of this study is to assess in France the impact of Prevenar on the possible evolution of the pneumococcal serotypes distribution and antibiotic resistance in NP samples of children with AOM.
- Conditions
- Otitis Media, Otitis Media With Effusion, Pneumococcal Infections
- Trial name
- NCT00195611
- Testing
- Prevenar
- Where
- 35 sites in France
- Volunteers
- 3,293 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infectious Disease
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months.
- Trial name
- NCT07333352
- Testing
- 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)
- Where
- 7 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Diphtheria, Tetanus
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when…
- Conditions
- Diphtheria, Tetanus, Haemophilus Infection, Pertussis
- Trial name
- NCT00772928
- Testing
- Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
- Where
- 23 sites in United States
- Volunteers
- 1,167 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infectious Diseases
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China.
- Trial name
- NCT02285036
- Testing
- vaccination PPV23, vaccination PNEUMOVAX 23
- Where
- China
- Volunteers
- 1,660 people
- Sponsor
- Walvax Biotechnology Co., Ltd.
HIV Infections, Pneumococcal Infections
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a…
- Trial name
- NCT00962780
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), Blood draw
- Where
- 11 sites in Romania, South Africa
- Volunteers
- 303 people
- Sponsor
- Pfizer
Meningococcal Meningitis, Measles
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00422292
- Testing
- Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,664 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infectious Disease
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years.
- Trial name
- NCT06183216
- Testing
- Sinovac PCV13, PREVNAR 13
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in children aged 2 Months (Minimum 6 Weeks) to 17 Years .
- Trial name
- NCT06675032
- Testing
- PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meningitis, Measles
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
This is a Phase III, modified single-blind, randomized, parallel-group, multicenter, comparative trial in the United States designed to evaluate the immunogenicity and safety of two doses of Menactra vaccine administered alone…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00384397
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 39 sites in United States
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company